M Bio Technology Inc.

Basic information

Location (HQ)

Tokyo, JP

Other location(s)

Chiba, JP

Spinout from

Website

CEO

Established in 

Kazuhiro Matsuda

2005

Business descriptions

M Biotech has key patents for the structure of glycolipid on mycoplasma membrane surfaces as well as its synthesis methodology. These technologies could be applied both for high sensitive diagnoses and vaccine development with applying the glycolipid-antigen to produce its antibody. M Biotech encourages global business expansion with identifying the business and technical partners.

Business field

Keywords

Mycoplasma

Glycolipid

Antigen

Vaccine

TRL

5

Key literatures

Synthesis and absolute structures of Mycoplasma pneumoniae β-glyceroglycolipid antigens

Chemosynthetic homologues of Mycoplasma pneumoniae β-glycolipid antigens for the diagnosis of mycoplasma infectious diseases

Detection of serum antibodies against phosphocholine-containing aminoglycoglycerolipid specific to Mycoplasma fermentans in HIV-1 infected individuals

Company values

Number of filed patents

2

Patent IDs

Please ask

Total patent value (USD)

Over $3m

Business stage

Series B stage / global alliance

Types of requested collaborations

R&D Collaboration, Oversea business partners

Ideal exit model

Licensing out

Introduction

M Biotech has key patents for the structure of glycolipid on mycoplasma membrane surfaces as well as its synthesis methodology. These technologies could be applied both for high sensitive diagnoses and vaccine development with applying the glycolipid-antigen to produce its antibody. M Biotech encourages global business expansion with identifying the business and technical partners.

Licensing opportunity

Licensing is also available especially in the field of vaccine development. Please ask for details.

Investment opportunity